Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):463–465. doi: 10.1038/bjc.1991.108

Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.

V Raina 1, D Cunningham 1, N Gilchrist 1, M Soukop 1
PMCID: PMC1971849  PMID: 2003990

Abstract

Thirty-four patients with progressive low grade non-Hodgkin's lymphoma were treated with 1 microgram oral alfacalcidol daily. Complete response was seen in four patients and a partial response in four patients with an overall response rate of 24%. Median duration of response was 14 months. Disease stabilised in ten other patients (29%) and 16 patients (47%) had tumour progression. In the sub-group of patients with follicular, small-cleaved cell-lymphoma the overall response to treatment was 29%. Apart from one patient who had a mild transitory elevation of serum calcium there was no recorded toxicity from alfacidol. These results indicate that alfacalcidol has significant antitumour activity in patients with low grade non-Hodgkin's lymphoma of the follicular, small-cleaved cell type.

Full text

PDF
463

Images in this article

464Figure 1
on p.464

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barsony J., Marx S. J. Receptor-mediated rapid action of 1 alpha,25-dihydroxycholecalciferol: increase of intracellular cGMP in human skin fibroblasts. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1223–1226. doi: 10.1073/pnas.85.4.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chouvet C., Vicard E., Devonec M., Saez S. 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem. 1986 Jan;24(1):373–376. doi: 10.1016/0022-4731(86)90085-3. [DOI] [PubMed] [Google Scholar]
  3. Colston K., Colston M. J., Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981 Mar;108(3):1083–1086. doi: 10.1210/endo-108-3-1083. [DOI] [PubMed] [Google Scholar]
  4. Colston K., Colston M. J., Fieldsteel A. H., Feldman D. 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982 Mar;42(3):856–859. [PubMed] [Google Scholar]
  5. Cunningham D., Gilchrist N. L., Cowan R. A., Forrest G. J., McArdle C. S., Soukop M. Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Br Med J (Clin Res Ed) 1985 Oct 26;291(6503):1153–1155. doi: 10.1136/bmj.291.6503.1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eisman J. A., Barkla D. H., Tutton P. J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987 Jan 1;47(1):21–25. [PubMed] [Google Scholar]
  7. Frampton R. J., Suva L. J., Eisman J. A., Findlay D. M., Moore G. E., Moseley J. M., Martin T. J. Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture. Cancer Res. 1982 Mar;42(3):1116–1119. [PubMed] [Google Scholar]
  8. Horning S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984 Dec 6;311(23):1471–1475. doi: 10.1056/NEJM198412063112303. [DOI] [PubMed] [Google Scholar]
  9. Lee M. S., Chang K. S., Cabanillas F., Freireich E. J., Trujillo J. M., Stass S. A. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science. 1987 Jul 10;237(4811):175–178. doi: 10.1126/science.3110950. [DOI] [PubMed] [Google Scholar]
  10. Lemire J. M., Adams J. S., Sakai R., Jordan S. C. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest. 1984 Aug;74(2):657–661. doi: 10.1172/JCI111465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Manolagas S. C., Provvedini D. M., Murray E. J., Murray S. S., Tsonis P. A., Spandidos D. A. Association between the expression of the c-myc oncogene mRNA and the expression of the receptor protein for 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1987 Feb;84(3):856–860. doi: 10.1073/pnas.84.3.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Provvedini D. M., Tsoukas C. D., Deftos L. J., Manolagas S. C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983 Sep 16;221(4616):1181–1183. doi: 10.1126/science.6310748. [DOI] [PubMed] [Google Scholar]
  14. Schein P. S., Chabner B. A., Canellos G. P., Young R. C., DeVita V. T., Jr Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. Cancer. 1975 Feb;35(2):354–357. doi: 10.1002/1097-0142(197502)35:2<354::aid-cncr2820350209>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Tsoukas C. D., Provvedini D. M., Manolagas S. C. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science. 1984 Jun 29;224(4656):1438–1440. doi: 10.1126/science.6427926. [DOI] [PubMed] [Google Scholar]
  16. Wiernik P. H. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976 Nov;44:35–38. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES